Board approved Q2 and H1 FY26 unaudited financial results

Results View source PDF Explain this filing

UNICHEMLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.9%Reaction day

₹456.10

prior close

₹471.55

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+5.2% vs market

Pharmaceuticals peers, median of 157sector-0.2%+5.1% vs sector

On the reaction day the stock moved 5.2 pts more than Nifty Microcap 250 and 5.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.9

10m

+2.0

15m

+1.9

30m

+3.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.9-0.3+5.2-0.2+5.1

Next day

+4.4+0.7+3.8+0.5+3.9

+2.2+0.6+1.6+0.6+1.6

+2.8+0.5+2.3+0.3+2.5

+3.7+1.1+2.7+0.2+3.5

+4.2+0.3+3.9-0.6+4.8

+4.8-0.2+5.0-1.1+5.9

15d

-0.5-2.2+1.8-2.1+1.6

+1.1-4.9+6.0-3.2+4.3

-9.1-7.5-1.7-5.8-3.3

-16.1-4.8-11.3-6.4-9.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Unichem Laboratories' Board of Directors, at its meeting on November 11, 2025, approved the unaudited standalone and consolidated financial statements for the second quarter and half year ended September 30, 2025, along with the auditors' limited review report. The results will be uploaded to the company and exchange websites.

Likely market impact

Routine intimation of results approval; investors should review the detailed financials for actual earnings performance.